Rapamycin analogs
Rapamycin analogs has been studied in 124 papers since 2004: 22 trials and 12 observational studies in people, 25 in animals, 19 in cells, 35 reviews; 35 in the past year. The newest paper, Oct 30, 2026: “Everolimus-induced Regression of a Low-grade Oncocytic Renal Tumour in a Germline TSC1 Carrier: Expanding the Therapeutic and Phenotypic Spectrum of Tuberous Sclerosis Complex-Associated…”.
124 papers study it16 more mention it155 findingsUpdated
Research on it is growing 32% faster than aging research as a whole: 10 papers in the latest year counted
1 new paper in 30 daysSee all 137 papers on rapamycin analogs
At a glance
Independent labs found the same change in cells, worms or flies and people. 45 independent labs in 16 countries; 821 trials, 5 about aging, 303 with no results posted.
“The most common grade 3 or 4 adverse events were stomatitis (8% in the combination-therapy group vs. 1% in the exemestane-alone group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).”
9 of its findings point the other way.
- 45 independent labs in 16 countries
- 9 findings against
- 821 trials, 5 about aging, 303 with no results posted
- Funders: National Institutes of Health and others
- 53 of 151 findings with company ties
- 293 of 821 trials sponsored by its developers
- Human trial22
- Humans11
- Animals19
- Model organisms6
- Cells18
- In silico3
Studies in people
See all 19 studies of rapamycin analogs in people19 studies gave rapamycin analogs to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves progression-free survival11.8 months vs 1.8 months no change: Has no effect on overall survival38.3 vs 38.2 months | Randomized trial | 30 peopleMetastatic GEP-NEN or LCNEC after first-line chemotherapy | The oncologist, Jan 23, 2026 |
up: Increases seroconversion56% vs 13% up: Increases SARS-CoV-2 IgG antibodies160 AU/mL (0–142) vs 0 AU/mL (0–0) no change: Has no effect on cellular response44% vs 50% | Randomized trial28 d | 32 people12 (38%) were female72 ± 4 yElderly (≥65 y), de novo KTRs | Transplantation, May 11, 2022 |
down: Lowers the risk of infectionP = 0.001 up: Increases antiviral gene expression up: Improves influenza vaccination response | Randomized trial6 weeks | 264 peopleelderlyOlder adults; elderly subjects, low-dose combination given for 6 weeks | Science translational medicine, Jul 11, 2018 |
no change: Has no effect on everolimus pharmacokinetic parameters across timepointsCtrough 4.7 ± 2.5 ng/mL; AUC0-12h 106 ± 51 ng/h per mL | Trialfirst 6 months after transplantation | 16 peopleBothmean 64 yearsOlder adults; with steady-state tacrolimus | Transplantation, Sep 1, 2017 |
down: Decreases seizure frequencymedian reduction 39.6% high exposure and 29.3% low exposure vs 14.9% placebo up: Increases seizure response rate40.0% vs 15.1% with placebo up: Increases grade 3 or 4 adverse events24% high exposure, 18% low exposure, 11% placebo | Randomized trial12-week maintenance period | 366 people2-65 yearsAdjunctive therapy in tuberous sclerosis complex with treatment-resistant focal-onset seizures | Lancet (London, England), Sep 6, 2016 |
What did lifespan studies of rapamycin analogs find?
DrugAgeDrugAge records 1 result from 1 paper: 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.
What did studies of rapamycin analogs find?
105Studies of rapamycin analogs measured 105 outcomes; the most studied are progression-free survival (6 studies), seizure frequency (4) and cellular senescence (4).
Progression-free survival
upin humans6no changein humans1HR 0.43–0.89
6 studies
Progression-free survival
upin humans6no changein humans1HR 0.43–0.89
Everolimus improves progression-free survival in humans (metastatic GEP-NEN or LCNEC after first-line chemotherapy) (11.8 months vs 1.8 months).
“Median (m)PFS was 11.8 months in the everolimus arm and 1.8 months in the control arm.”
Human trialmetastatic GEP-NEN or LCNEC after first-line chemotherapy10 mg/day
The oncologist
Everolimus improves progression-free survival in humans (11.0 vs 3.9 months).
“Median PFS assessed by central review was 11.0 months (95% CI, 9.2–13.3) in the everolimus arm and 3.9 months (95% CI, 3.6–7.4) in the placebo arm.”
Human trialn = 302
Lancet (London, England)
Everolimus increases progression-free survival in humans (hormone receptor-negative subpopulation, added to trastuzumab and paclitaxel) (median 20.27 vs 13.08 months (+7.2 months); HR 0.66).
“hazard ratio 0·66, 95% CI 0·48-0·91; p=0·0049”
Human trialhormone receptor-negative subpopulation, added to trastuzumab and paclitaxel10 mg once a dayn = 311
The Lancet. Oncology
Everolimus showed no clear effect on progression-free survival in humans (added to trastuzumab and paclitaxel; full study population) (HR 0.89, 95% CI 0.73-1.08; median 14.95 vs 14.49 months).
“hazard ratio 0·89, 95% CI 0·73-1·08; p=0·1166”
Human trialadded to trastuzumab and paclitaxel; full study population10 mg once a dayn = 719
The Lancet. Oncology
Everolimus improves progression-free survival in humans (previously treated advanced gastric cancer, compared with best supportive care) (median PFS 1.7 vs 1.4 months; HR 0.66).
“Median PFS was 1.7 months and 1.4 months in the everolimus and placebo arms, respectively (hazard ratio, 0.66; 95% CI, 0.56 to 0.78).”
Human trialpreviously treated advanced gastric cancer, compared with best supportive care10 mg/dn = 656
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Everolimus improves progression-free survival in humans (added to exemestane, compared with placebo plus exemestane) (median 6.9 vs 2.8 months (local assessment); HR 0.43 (95% CI 0.35 to 0.54)).
“Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors.”
Human trialadded to exemestane, compared with placebo plus exemestanen = 724
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
The New England journal of medicine
Everolimus improves progression-free survival in conjunction with exemestane (6.9 vs 2.8 months).
“The trial met its primary end point, progression-free survival; the median progression-free survival, on the basis of radiographic studies assessed by the local investigators, was 6.9 months for everolimus plus exemestane versus 2.8 months for placebo plus exemestane (hazard ratio for progression or death, 0.43; 95% confidence interval [CI], 0.35 to 0.54; P<0.001”
Human trialin conjunction with exemestanemedian duration of exposure to everolimus was 14.6 weeksfemalesn = 724
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
The New England journal of medicine
Everolimus improves progression-free survival in humans (median PFS 16.4 vs 11.3 months; HR 0.77 (95% CI 0.59-1.00)).
“Everolimus plus octreotide LAR, compared with placebo plus octreotide LAR, improved progression-free survival in patients with advanced neuroendocrine tumours associated with carcinoid syndrome.”
Human trialin combination with octreotide LAR, versus placebo plus octreotide LAR, in advanced neuroendocrine tumor with carcinoid syndrome10 mg per dayn = 429
Lancet (London, England)
Seizure frequency
downin humans4
4 studies
Seizure frequency
downin humans4
Everolimus decreases seizure frequency in humans (median reduction 39.6% high exposure and 29.3% low exposure vs 14.9% placebo).
“Adjunctive everolimus treatment significantly reduced seizure frequency with a tolerable safety profile compared with placebo”
Human trialadjunctive therapy in tuberous sclerosis complex with treatment-resistant focal-onset seizures12-week maintenance periodn = 366
Lancet (London, England)
Everolimus decreases seizure frequency in humans (tuberous sclerosis complex with medically refractory epilepsy) (median reduction of 73%; 12 of 20 with at least 50% reduction).
“Overall, seizures were reduced in 17 of the 20 by a median reduction of 73% (p<0.001).”
Human trialtuberous sclerosis complex with medically refractory epilepsy12 weeksn = 20
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Annals of neurology
Everolimus decreases seizure frequency in humans (median change -1 seizure).
“seizure frequency for the 6-month study period (vs. the previous 6-month period) decreased in 9, did not change in 6, and increased in 1 (median change, -1 seizure; P=0.02)”
Human trial6 monthsn = 16
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
The New England journal of medicine
Everolimus is linked with lower seizure frequency in humans (patient with tuberous sclerosis complex and refractory seizures).
“A significant reduction in seizure frequency and improvement in facial angiofibromas were observed during the follow-up period.”
Humanspatient with tuberous sclerosis complex and refractory seizures
Frontiers in genetics
Cellular senescence
downin human cells2upin mice1downin reviews1
4 studies
Cellular senescence
downin human cells2upin mice1downin reviews1
Everolimus induces cellular senescence in mice during treatment.
“An induction of senescence as well as differential expression of genes responsible for metabolism was also observed”
Animalsduring treatment
Frontiers in oncology
Temsirolimus decreases cellular senescence in human cells (IL-1β-induced senescence) (95% CI -0.534 to -0.327).
“senescent senescence-associated beta-galactosidase (SA-β-gal) positivity (versus rapamycin, 95% CI -0.437 to -0.230; temsirolimus, 95% CI -0.534 to -0.327”
CellsIL-1β-induced senescencenucleus pulposus cells
Osteoarthritis and cartilage
Everolimus decreases cellular senescence in fibroblasts from laminopathy patients with different LMNA mutations.
“Everolimus treatment increased proliferative ability and delayed senescence in all cell lines.”
Cellsin fibroblasts from laminopathy patients with different LMNA mutationsfibroblastn = 6
Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts
Proceedings of the National Academy of Sciences of the United States of America
Rapamycin analogs decrease cellular senescence.
“Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence.”
Review
From rapalogs to anti-aging formula
Oncotarget
Stomatitis
upin humans4
4 studies
Stomatitis
upin humans4
Everolimus induces stomatitis in humans (grade 3 or 4 drug-related adverse events; versus placebo) (9% (18 of 202) vs 0% (0 of 98)).
“stomatitis (in 18 [9%] of 202 patients in the everolimus group vs 0 of 98 in the placebo group)”
Human trialgrade 3 or 4 drug-related adverse events; versus placebo10 mg per dayn = 202
Lancet (London, England)
Everolimus increases stomatitis in humans (added to trastuzumab and paclitaxel) (67% vs 32% of patients).
“stomatitis (314 [67%] of 472 patients in the everolimus group vs 77 [32%] of 238 patients in the placebo group)”
Human trialadded to trastuzumab and paclitaxel10 mg once a day
The Lancet. Oncology
Everolimus increases stomatitis in humans (versus placebo) (48% (38 of 79) with everolimus vs 8% (3 of 39) with placebo).
“The most common adverse events in the everolimus and placebo groups were stomatitis (48% [38 of 79], 8% [3 of 39], respectively)”
Human trialversus placebo10 mg per dayn = 118
Lancet (London, England)
Everolimus increases stomatitis in combination with octreotide LAR, versus placebo plus octreotide LAR (62% vs 14% (all-grade adverse events)).
“adverse events of all grades included stomatitis (62%vs 14%)”
Human trialin combination with octreotide LAR, versus placebo plus octreotide LAR10 mg per dayn = 429
Lancet (London, England)
Lifespan
upin worms2upin mice1
3 studies
Lifespan
upin worms2upin mice1
Temsirolimus extends lifespan in worms.
“The rapalog temsirolimus extended lifespan similarly to rapamycin.”
Model organisms
Using Drugs to Slow Aging in the Nematode Caenorhabditis Elegans
GSA 2025 abstract
Temsirolimus extends lifespan in worms.
“The rapalog temsirolimus extended lifespan similarly to rapamycin”
Model organisms
Characterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans
The journals of gerontology. Series A, Biological sciences and medical sciences
Everolimus extends lifespan in MOG35-55-immunized NOD mice.
“mTOR inhibitors rapamycin and everolimus delayed disease progression and robustly extended survival of immunized mice”
Animalsin MOG35-55-immunized NOD micefemales
Neurobiology of disease
Cell proliferation
upin human cells2downin human cells1−48%
3 studies
Cell proliferation
upin human cells2downin human cells1−48%
Everolimus increases cell proliferation in fibroblasts from laminopathy patients with different LMNA mutations.
“Everolimus treatment increased proliferative ability and delayed senescence in all cell lines.”
Cellsin fibroblasts from laminopathy patients with different LMNA mutationsfibroblastn = 6
Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts
Proceedings of the National Academy of Sciences of the United States of America
Temsirolimus increases cell proliferation in human cells.
“temsirolimus decreases progerin levels, increases proliferation”
Cells
Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype
PloS one
Everolimus inhibits cell proliferation in human cells (-48%).
“Everolimus significantly suppressed the growth of TT cells [median inhibition concentration (IC50) 0.33 nM, maximal inhibition of proliferation: −48%] in a dose-dependent manner after 6 days of incubation.”
Cellsmales
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
Journal of cellular and molecular medicine
Overall survival
no changein humans2HR 0.9
2 studies
Overall survival
no changein humans2HR 0.9
Everolimus showed no clear effect on overall survival in humans (metastatic GEP-NEN or LCNEC after first-line chemotherapy) (38.3 vs 38.2 months).
“MOS was similar between arms (38.3 and 38.2 months).”
Human trialmetastatic GEP-NEN or LCNEC after first-line chemotherapy10 mg/day
The oncologist
Everolimus showed no clear effect on overall survival in humans (previously treated advanced gastric cancer, compared with best supportive care) (median OS 5.4 vs 4.3 months; HR 0.90).
“Median OS was 5.4 months with everolimus and 4.3 months with placebo (hazard ratio, 0.90; 95% CI, 0.75 to 1.08; P = .124)”
Human trialpreviously treated advanced gastric cancer, compared with best supportive care10 mg/dn = 656
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Autophagy
upin human cells2
2 studies
Autophagy
upin human cells2
Temsirolimus increases autophagy in human cells.
“Further, temsirolimus treatment enhanced autophagic activity in human chondrocytes.”
Cells
Connective tissue research
Everolimus activates autophagy in human cells.
“Everolimus (Ever) upregulated autophagy and broadly alleviated inflammatory cytokines produced by multiple T cell subsets.”
CellsCD4+ T cell0.01 μM
GeroScience
Total cholesterol
upin humans2
2 studies
Total cholesterol
upin humans2
Everolimus increases total cholesterol in humans during everolimus treatment in TSC-RAML patients.
“Aspartate transaminase (AST), Alanine transferase (ALT), total cholesterol (TC), and triglyceride (TG) increased significantly during everolimus treatment (P < 0.05)”
Human trialduring everolimus treatment in TSC-RAML patientsyear-long
Discover oncology
Rapamycin analogs increase total cholesterol in individuals with ageing-related diseases.
“there were increased numbers of infections and increases in total cholesterol, LDL cholesterol, and triglycerides in individuals with ageing-related diseases”
Reviewin individuals with ageing-related diseases
Targeting ageing with rapamycin and its derivatives in humans: a systematic review
The lancet. Healthy longevity
Reactive oxygen species
downin cells1downin human cells1
2 studies
Reactive oxygen species
downin cells1downin human cells1
Everolimus decreases reactive oxygen species in HGPS fibroblasts.
“We found that both drugs effectively reduced cellular ROS levels.”
Cellsin HGPS fibroblasts
Peroxisomal abnormalities and catalase deficiency in Hutchinson-Gilford Progeria Syndrome
Aging
Everolimus decreases reactive oxygen species in cells (insulin-treated cultured cells).
“They showed protective properties against genotoxic damage and significantly reduced ROS after in vitro treatment of cultured cells with insulin.”
Cellsinsulin-treated cultured cells
Molecules (Basel, Switzerland)
Quality of life
upin humans2
2 studies
Quality of life
upin humans2
Everolimus improves quality of life in humans (tuberous sclerosis complex with medically refractory epilepsy).
“Significant reductions in seizure duration and improvement in parent-reported behavior and quality of life were also observed.”
Human trialtuberous sclerosis complex with medically refractory epilepsy12 weeksn = 20
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Annals of neurology
Everolimus increases quality of life in humans (mean 63.4 at 3 months and 62.1 at 6 months vs 57.8 at baseline).
“was improved at 3 months (63.4±12.4) and 6 months (62.1±14.2) over the baseline score (57.8±14.0)”
Human trial
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
The New England journal of medicine
Estimated glomerular filtration rate
upin humans1no changein humans1
1 study
Estimated glomerular filtration rate
upin humans1no changein humans1
Everolimus improves estimated glomerular filtration rate in humans (patients with tumor volume reduction ≥500 ml) (101 [95, 119] vs 115 [99, 122] ml/min/1.73 m2, p = 0.009).
“Notably, patients with a tumor volume reduction (TVR) of ≥500 ml showed a significant improvement in eGFR”
Human trialpatients with tumor volume reduction ≥500 ml1-yr
European urology open science
Everolimus showed no clear effect on estimated glomerular filtration rate in humans (overall cohort of TSC-RAML patients) (102 [81-121] vs 103 [79-122] ml/min/1.73 m2, p = 0.8).
“After 1 yr of everolimus treatment, no significant change in eGFR was observed in the overall cohort of 54 patients”
Human trialoverall cohort of TSC-RAML patients1-yrn = 54
European urology open science
Calcitonin
downin humans1
1 study
Calcitonin
downin humans1
Everolimus decreases calcitonin in humans (combined with octreotide LAR) (86% in patient 1; 42% in patient 2).
“Serum calcitonin decreased by 86% in patient 1 and by 42% in patient 2.”
Human trialcombined with octreotide LAR5-10 mg/dayn = 2
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
Journal of cellular and molecular medicine
Everolimus decreases calcitonin.
“This change in the dose of everolimus resulted in a marked decrease of serum calcitonin, which was substantially unchanged after the first month of treatment with 5 mg a day ( and D).”
Human trial
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study
Journal of cellular and molecular medicine
Overall response rate
upin humans1
1 study
Overall response rate
upin humans1
Everolimus improves overall response rate in humans (single-agent, relapsed/refractory aggressive NHL) (ORR 30% (95% CI 20-41%)).
“The overall response rate (ORR) was 30% (95% confidence interval: 20-41%)”
Human trialsingle-agent, relapsed/refractory aggressive NHL10 mg dailyn = 77
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Leukemia
Everolimus improves overall response rate in humans (30% (23/77; 95% CI: 20 - 41%)).
“The ORR was 30% (23/77; 95% CI: 20 - 41%) with 20 PR and 3 CRu.”
Human trialmedian of 2.0 monthsn = 77
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Leukemia
Depressive symptoms
no changein humans1downin humans1
1 study
Depressive symptoms
no changein humans1downin humans1
Everolimus showed no clear effect on depressive symptoms in humans (switch from calcineurin inhibitors to everolimus, four weeks after switching) (Z = -0.595; P = .552).
“DS (Z = -1.18; P = .236) and HAMD (Z = -0.595; P = .552) remained unchanged”
Human trialswitch from calcineurin inhibitors to everolimus, four weeks after switching4 weeksn = 9
Transplantation proceedings
Everolimus decreases depressive symptoms in humans (switch from calcineurin inhibitors to everolimus, four weeks after switching) (Z = -1.14; P = .048).
“Four weeks after switching to CNI-free immunosuppression using everolimus, BDI (Z = -1.14; P = .048)”
Human trialswitch from calcineurin inhibitors to everolimus, four weeks after switching4 weeksn = 9
Transplantation proceedings
All 105Fewer
What is rapamycin analogs linked with?
19Studies link rapamycin analogs with 19 measures, among them ascites, heart failure and pleural effusion.
Ascites
upin humans1
1 study
Ascites
upin humans1
Temsirolimus is associated with ascites in humans (disproportionality signal in FAERS reports; not in drug label).
“the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”
Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929
Naunyn-Schmiedeberg's archives of pharmacology
Heart failure
upin humans1
1 study
Heart failure
upin humans1
Temsirolimus is associated with heart failure in humans (disproportionality signal in FAERS reports; not in drug label).
“the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”
Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929
Naunyn-Schmiedeberg's archives of pharmacology
Pleural effusion
upin humans1
1 study
Pleural effusion
upin humans1
Temsirolimus is associated with pleural effusion in humans (disproportionality signal in FAERS reports; not in drug label).
“the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”
Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929
Naunyn-Schmiedeberg's archives of pharmacology
Dehydration
upin humans1
1 study
Dehydration
upin humans1
Temsirolimus is associated with dehydration in humans (disproportionality signal in FAERS reports; not in drug label).
“the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”
Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929
Naunyn-Schmiedeberg's archives of pharmacology
128 adverse event preferred terms
upin humans1
1 study
128 adverse event preferred terms
upin humans1
Temsirolimus is associated with 128 adverse event preferred terms in humans.
“Through disproportionality analysis, we identified 128 preferred terms (PTs) associated with temsirolimus across 17 organ systems.”
Humansdisproportionality analysis of FAERS reports; signal when ROR, PRR, BCPNN and EBGM all meet thresholdn = 2,929
Naunyn-Schmiedeberg's archives of pharmacology
LGALS1
mixedin human cells1
1 study
LGALS1
mixedin human cells1
Everolimus is associated with LGALS1 in KMT2Ar-ALL cells.
“inhibition of the mTOR pathway with everolimus modulated Galectin-1 expression in these cells”
Cellsin KMT2Ar-ALL cells
mTOR Modulation Affects Galectin-1 Expression in KMT2A-rearranged Acute Lymphoblastic Leukemia Cells
Anticancer research
Dry age-related macular degeneration
upin humans1HR 2.14
1 study
Dry age-related macular degeneration
upin humans1HR 2.14
Everolimus is linked with a higher risk of dry age-related macular degeneration in humans (HR 2.14, 95% CI 1.24-3.69).
“everolimus had an increased hazard of dry AMD (HR = 2.14, 95% CI 1.24-3.69, p < 0.01)”
Humans
Systemic immunosuppression and risk of age-related macular degeneration
PloS one
Infection
downin humans1
1 study
Infection
downin humans1
Everolimus lowers the risk of infection in humans (elderly subjects, low-dose combination given for 6 weeks) (P = 0.001).
“was associated with a significant (P = 0.001) decrease in the rate of infections reported by elderly subjects for a year after study drug initiation”
Human trialelderly subjects, low-dose combination given for 6 weekslow-dose6 weeksn = 264
TORC1 inhibition enhances immune function and reduces infections in the elderly
Science translational medicine
Glucose intolerance
upin reviews1
1 study
Glucose intolerance
upin reviews1
Rapamycin analogs are associated with glucose intolerance (chronic treatment).
“the chronic inhibition of mTOR by macrolide rapamycin or other rapalogs has been associated with glucose intolerance and insulin resistance”
Reviewchronic treatment
mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?
Oxidative medicine and cellular longevity
Death
downin humans1HR 0.64
1 study
Death
downin humans1HR 0.64
Everolimus lowers the risk of death in humans (first pre-planned interim overall survival analysis; versus placebo) (HR 0.64 (95% CI 0.40-1.05), not statistically significant).
“everolimus might be associated with a reduction in the risk of death (HR 0·64 [95% CI 0·40-1·05]”
Human trialfirst pre-planned interim overall survival analysis; versus placebo10 mg per dayn = 302
Lancet (London, England)
Progression or death
downin humans1HR 0.48
1 study
Progression or death
downin humans1HR 0.48
Everolimus lowers the risk of progression or death in humans (HR 0.48 (95% CI 0.35-0.67); median PFS 11.0 vs 3.9 months).
“Everolimus was associated with a 52% reduction in the estimated risk of progression or death (hazard ratio [HR] 0·48 [95% CI 0·35-0·67], p<0·00001).”
Human trialadvanced, progressive neuroendocrine tumors of lung or gastrointestinal origin; versus placebo10 mg per dayn = 302
Lancet (London, England)
Mortality
downin humans1HR 0.64
1 study
Mortality
downin humans1HR 0.64
Everolimus lowers the risk of mortality in humans (HR 0.64, 95% CI 0.40–1.05).
“The survival results from the first interim OS analysis favoured everolimus with 36% reduction in the estimated risk relative to placebo, although statistical significance was not attained (HR, 0.64; 95% CI, 0.40–1.05; p=0.037; Lan-DeMets O’brian Fleming boundary for significance at first interim analysis, 0.0002”
Human trialn = 302
Lancet (London, England)
Disease progression or death
downin humans1HR 0.48
1 study
Disease progression or death
downin humans1HR 0.48
Everolimus lowers the risk of disease progression or death in humans (HR 0.48, 95% CI 0.35–0.67).
“Everolimus was associated with a 52% reduction in the estimated risk of disease progression or death (HR, 0.48; 95% CI, 0.35–0.67; p<0.00001).”
Human trialn = 302
Lancet (London, England)
Stomatitis
upin humans1
1 study
Stomatitis
upin humans1
Everolimus raises the risk of stomatitis in conjunction with exemestane (8% vs. 1%).
“The most common grade 3 or 4 adverse events were stomatitis (8% in the combination-therapy group vs. 1% in the exemestane-alone group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%).”
Human trialin conjunction with exemestanemedian duration of exposure to everolimus was 14.6 weeksfemalesn = 724
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
The New England journal of medicine
Thrombocytopenia
upin humans1
1 study
Thrombocytopenia
upin humans1
Everolimus raises the risk of thrombocytopenia in humans (versus ciclosporin-based regimen).
“thrombocytopenia, aphthous stomatitis, and diarrhoea also occurred more often in the everolimus group”
Human trialversus ciclosporin-based regimen
Lancet (London, England)
All 19Fewer
Trials
5 of 821 about agingAbout aging
Phase 2Completed
Rapalog Pharmacology (RAP PAC) Study
Phase 1Recruiting
RESTOR: PK/PD mTORi Inhibition in Older Adults
Early phase 1Recruiting
Phase 2Completed
Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)
Phase 2Status unknown
- EverolimusApproved 2009
- TemsirolimusApproved 2007
Who is developing rapamycin analogs?
3 companies: Novartis Pharmaceuticals, Chong Kun Dang Pharmaceutical and Eisai.
Trial sponsors
Novartis Pharmaceuticals Corporation
Company117 trialsPhase 424,564 people
Company7 trialsPhase 41,643 people
Company2 trialsPhase 4252 people
Company2 trialsPhase 4149 people
Company6 trialsPhase 31,697 people
Company5 trialsPhase 31,625 people
Company2 trialsPhase 3408 people
Janssen Research & Development
Company1 trialPhase 3280 people
Funding
1 grant since 2018National Eye Institute$1.3M